Views & Analysis Transparently opaque: drug list prices versus net prices The pros and cons of keeping drug pricing agreements confidential.
News MSD says subcutaneous Keytruda matches IV form A subcutaneous formulation of MSD's top-selling cancer immunotherapy Keytruda was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings.
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
